Need Help?

nEODURVARIB clinical trial. Exome sequencing in advanced urothelial carcinoma

Exome sequencing (BAM and VCF files) in advanced urothelial carcinoma in diagnostic and pos-ttreatment samples

Request Access

Data sharing policy from exome sequencing data from NCT03534492 (Neodurvarib Clinical Trial)

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom the Laboratory of Innovation in Oncology at HM Sanchinarro (herein after LIO-HMS) grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: HM Sanchinarro nd the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. LIO-HMS: Laboratory of Innovation in Oncology at HM Sanchinarro Hospital Universitario HM Sanchinarro, Madrid, Spain 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify LIO-HMS within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify LIO-HMS prior to any significant changes to the protocol for the Project. 14. The User Institution will notify LIO-HMS as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. LIO-HMS may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than LIO-HMS. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000000791 Exome Sequencing

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF50000277755 bam 4.1 GB
EGAF50000277756 bam 8.0 GB
EGAF50000277757 bam 10.1 GB
EGAF50000277758 bam 3.8 GB
EGAF50000277759 bam 8.4 GB
EGAF50000277760 bam 9.5 GB
EGAF50000277761 bam 5.7 GB
EGAF50000277762 bam 10.7 GB
EGAF50000277763 bam 3.5 GB
EGAF50000277764 bam 4.0 GB
EGAF50000277765 bam 9.0 GB
EGAF50000277766 bam 7.3 GB
EGAF50000277767 bam 9.2 GB
EGAF50000277768 bam 6.4 GB
EGAF50000277769 bam 8.0 GB
EGAF50000277770 bam 4.0 GB
EGAF50000277771 bam 4.1 GB
EGAF50000277772 bam 5.5 GB
EGAF50000277773 bam 9.6 GB
EGAF50000277774 bam 8.0 GB
EGAF50000277775 bam 5.1 GB
EGAF50000277776 bam 9.8 GB
EGAF50000277777 bam 6.8 GB
EGAF50000277778 bam 8.6 GB
EGAF50000277779 bam 8.9 GB
EGAF50000277780 bam 8.4 GB
EGAF50000277781 bam 4.0 GB
EGAF50000277782 bam 9.3 GB
EGAF50000277783 bam 9.2 GB
EGAF50000277784 bam 8.4 GB
EGAF50000277785 bam 9.2 GB
EGAF50000277786 bam 8.6 GB
EGAF50000277787 bam 3.7 GB
EGAF50000277788 bam 8.0 GB
EGAF50000277789 bam 7.2 GB
EGAF50000277790 bam 7.6 GB
EGAF50000277791 bam 6.9 GB
EGAF50000277792 bam 10.6 GB
EGAF50000277793 bam 5.1 GB
EGAF50000277794 bam 9.6 GB
EGAF50000277795 bam 3.7 GB
EGAF50000277796 bam 6.4 GB
EGAF50000277797 bam 6.3 GB
EGAF50000277798 bam 4.2 GB
EGAF50000277799 bam 3.8 GB
EGAF50000277800 bam 6.9 GB
EGAF50000277801 bam 3.9 GB
EGAF50000277802 bam 8.0 GB
EGAF50000277803 bam 7.2 GB
EGAF50000277804 bam 3.8 GB
EGAF50000277805 bam 3.5 GB
EGAF50000277806 bam 7.2 GB
EGAF50000277807 bam 3.5 GB
EGAF50000277808 bam 8.9 GB
EGAF50000277809 bam 4.7 GB
EGAF50000277810 bam 8.2 GB
EGAF50000277811 bam 7.7 GB
EGAF50000277812 bam 3.3 GB
EGAF50000277813 bam 3.8 GB
EGAF50000277814 bam 8.0 GB
EGAF50000277815 bam 5.0 GB
EGAF50000277816 bam 7.1 GB
EGAF50000277817 bam 4.2 GB
EGAF50000277818 bam 7.1 GB
EGAF50000277819 bam 6.8 GB
EGAF50000277820 bam 7.0 GB
EGAF50000277821 bam 7.2 GB
EGAF50000277822 bam 7.7 GB
EGAF50000277823 bam 8.3 GB
EGAF50000277824 bam 7.6 GB
EGAF50000277825 vcf 461.2 kB
EGAF50000277826 vcf 337.1 kB
EGAF50000277827 vcf 316.8 kB
EGAF50000277828 vcf 1.0 MB
EGAF50000277829 vcf 622.0 kB
EGAF50000277830 vcf 314.7 kB
EGAF50000277831 vcf 388.5 kB
EGAF50000277832 vcf 303.2 kB
EGAF50000277833 vcf 202.5 kB
EGAF50000277834 vcf 696.1 kB
EGAF50000277835 vcf 420.1 kB
EGAF50000277836 vcf 585.2 kB
EGAF50000277837 vcf 257.9 kB
EGAF50000277838 vcf 416.6 kB
EGAF50000277839 vcf 284.8 kB
EGAF50000277840 vcf 178.2 kB
EGAF50000277841 vcf 480.4 kB
EGAF50000277842 vcf 477.5 kB
EGAF50000277843 vcf 591.0 kB
EGAF50000277844 vcf 427.5 kB
EGAF50000277845 vcf 296.1 kB
EGAF50000277846 vcf 875.3 kB
EGAF50000277847 vcf 150.5 kB
EGAF50000277848 vcf 378.5 kB
EGAF50000277849 vcf 869.7 kB
EGAF50000277850 vcf 1.2 MB
EGAF50000277851 vcf 665.9 kB
EGAF50000277852 vcf 352.4 kB
EGAF50000277853 vcf 2.5 MB
EGAF50000277854 vcf 393.7 kB
EGAF50000277855 vcf 436.3 kB
EGAF50000277856 vcf 477.3 kB
EGAF50000277857 vcf 594.8 kB
EGAF50000277858 vcf 174.0 kB
EGAF50000277859 vcf 867.6 kB
EGAF50000277860 vcf 600.0 kB
EGAF50000277861 vcf 350.1 kB
EGAF50000277862 vcf 427.6 kB
EGAF50000277863 vcf 223.7 kB
EGAF50000277864 vcf 1.1 MB
EGAF50000277865 vcf 619.0 kB
EGAF50000277866 vcf 432.0 kB
EGAF50000277867 vcf 386.7 kB
EGAF50000277868 vcf 182.4 kB
114 Files (474.7 GB)